ESMO ADVANCED COURSE PROGRAMME

EGFR IN LUNG CANCER

Hong Kong SAR
26-27 January 2024

CO-CHAIRS
Tony S. K. Mok, Hong Kong SAR
Solange Peters, Switzerland

SPEAKERS
Lyudmila Bazhenova, United States
Enriqueta Felip, Spain
Rina Hui, Hong Kong SAR
Keith M. Kerr, United Kingdom
Molly S. C. Li, Hong Kong SAR
David Planchard, France
Suresh S. Ramalingam, United States
Daniel S. W. Tan, Singapore
James C.-H. Yang, Taiwan
Pan-Chyr Yang, Taiwan
Yi-Long Wu, China

LEARNING OBJECTIVES

- To understand the role of molecular diagnostic test on tissue and plasma samples for diagnosis, monitoring and TKI resistance in management of EGFR M+ lung cancer
- To comprehend management of early stage and local advanced EGFR M+ lung cancer
- To gain updated information on optimal first line management and treatment of TKI resistance
- To interrogate the potential use of immunotherapy for patients with EGFR M+ lung cancer

Friday, 26 January 2024

09:00-09:10  Welcome and introduction
Tony S. K. Mok, HKSAR
Solange Peters, CH

09:10-10:25  Session 1 – Diagnosis and early detection
(Chair: Keith M. Kerr, UK)

20’  Biomarker testing for NSCLC: Why should it be comprehensive and/or reflex?
Keith M. Kerr, UK

20’  The role of liquid biopsy in management of EGFR mutation positive lung cancer: Initial diagnosis, monitoring and resistance
Molly S. C. Li, HKSAR

20’  Early detection of lung cancer among never smokers
Pan-Chyr Yang, TW

15’  Discussion
10:25-10:55  Coffee break

10:55-11:50  Session 2 — Optimal standard of care  
(Chair: Solange Peters, CH)

20’  The art of optimal first line therapy for patients with sensitizing or uncommon EGFR mutation positive lung cancer  
Tony S. K. Mok, HKSAR

20’  Potential combination therapy for EGFR mutation positive lung cancer  
Rina Hui, HKSAR

15’  Discussion

11:50-12:45  Session 3 — EGFR TKI resistance  
(Chair: Tony S. K. Mok, HKSAR)

20’  Understanding and overcoming resistance to EGFR TKI: Mechanisms and dynamics  
David Planchard, FR

20’  Treatment strategy for management EGFR TKI resistance  
Lyudmila Bazhenova, US

15’  Discussion

12:45-13:45  Lunch

13:45-15:00  Session 4 — Early EGFR M+ NSCLC  
(Chair: Daniel S. W. Tan, SG)

20’  Adjuvant therapy for resectable EGFR mutation positive lung cancer  
Yi-Long Wu, CN

20’  How to manage stage III EGFR mutation positive lung cancer  
Suresh S. Ramalingam, US

20’  Next generation neo-adjuvant and adjuvant trials in EGFR M+ and other oncogene addicted lung cancer (excluding IO)  
Enriqueta Felip, ES

15’  Discussion

15:00-15:30  Coffee break

15:30-16:50  Session 5 — Facing the uncertainties  
(Chair: Suresh S. Ramalingam)

25’  Role of IO in early and advance stage EGFR M+ lung cancer  
Solange Peters, CH

20’  Biology and impact of co-mutations on management of EGFR M+ lung cancer  
Daniel S. W. Tan, SG

20’  Novel treatment approaches to EGFR M+ lung cancer  
James C.-H. Yang, US

15’  Discussion and closure of the day

19:00  Networking dinner
Saturday, 27 January 2024

09:00-12:30  Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

25’  Introduction based on clinical cases presented by speakers
30’  Discussion
5’  Break

Workshop 1  Oligometastasis, oligoprogression and systemic progression: How best to address
60’  Molly S. C. Li, HKSAR
     Suresh S. Ramalingam, US

Workshop 2  Interrogations for early stage EGFR M+ NSCLC
60’  David Planchard, FR
     Rina Hui, HKSAR

Workshop 3  Prevention and management of brain and leptomeningeal metastasis
60’  Daniel S. W. Tan, SG
     James C.-H. Yang, TW

11:00-11:30  Coffee break

11:30-12:30  Workshops continuation

12:30-13:00  Synthesis and wrap-up
Tony S. K. Mok, HKSAR
Solange Peters, CH

13:00-14:00  Lunch